2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006.

Slides:

Advertisements

Similar presentations

Direct costs and availability of diabetes medicines in low-income and middle-income countries Birgit Volman 27/08/2008 Meeting on Access to Medicines for.

Advertisements

1 Policy options to address access to chronic disease medicines Dr. Richard Laing Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical.

1 Medicines for Chronic Diseases: too costly, too scarce, too important to ignore Margaret Ewen Health Action International.

Completing the Medicine Price Data Collection form Presentation template for adaptation and use in medicine prices and availability survey training workshop.

1 Medicine Prices, Availability and Affordability Margaret Ewen Health Action International.

1 Introduction to the medicine prices and availability survey and training workshop Presentation template for adaptation and use in medicine prices and.

Understanding the Antimalarials Market in Uganda Rosette Mutambi, HEPS Uganda Martin Auton, Health Action International, The Netherlands ASTMH, December.

Management of ART in Albania : From the European Guidelines to the real practice. Arjan Harxhi MD, MSc, PhD University Hospital Center of Tirana Mother.

A brief overview of ART services at QECH, Malawi Kudzala Aub. MMEDsc. Student Sr. Lead ART Clinician/ HIV Medicine Registrar.

Ellen t Hoen, MSF Høsbjør, 8-11April 2001, WHO-WTO Workshop Differential Pricing 1 WHO-WTO Workshop Differential Pricing and Financing of Essential Drugs.

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.

Working Group 1: Best Use ARV for Children: Principles Simplified and standardized guidelines for ARV treatment of HIV-infected children are needed to.

Facility censuses and surveys Shanthi Noriega Minichiello, WHO Josibert Rubona, MoH,Tanzania Meeting on Health System Metrics Glion September, 2006.

Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies World Bank Training Program Jabulani Nyenwa, MD, MPH, MBA May 2005.

Price Reporting Mechanism (PRM): Lessons learnt and how to use the evidence from the PRM Technical Briefing Seminar for Consultants on Procurement and.

PROCURING AND DISTRIBUTING ARVs AND OTHER A.R.T COMMODITIES IN MALAWI Technical Briefing for Consultants in Procurement and Supply Management for HIV,

Access to paediatric ARV formulations Limitations due to regulations Experience from the field MSF.

A Call to Action Children – The missing face of AIDS.

Group III: Demand Forecasting

1 CHAI ARV Procurement Database Clinton Foundation HIV/AIDS Initiative November 7, 2005.

Harmonization of donor reporting requirements for antiretrovirals and related drugs Presented at the WHO meeting, Geneva ( October 2005) Oteba Olowo.

Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Accessing to ARV in HIV/AIDS care and treatment programme in Vietnam Dr.Nguyen Van.

From 3by5 to Universal Access – lessons learned and new challenges ODI Meetings Series Do big plans help big numbers? 7 th June 2006 Prof Charlie Gilks.

THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.

Fixed and Variable Costs. Median income per household member in the U.S. in 2006 was in the range from: 1)$15,000-20,000 2)$20,000-25,000 3)$25,000-30,000.

The 2013 Consolidated WHO Guidelines on ARV Use: Implementing to Achieve Maximum Impact Gottfried Hirnschall, MD, MPH Director, HIV/AIDS Department, WHO.

Public ARV Procurement Data: Using Information to Obtain Lower Prices Brenda Waning March 6, 2008 Open Society Institute Seminar Kiev, Ukraine Funded by.

World Health Organization

Drug Treatment Regimens: How and why WHO makes its global recommendations Prof Charles Gilks Director, Co-ordinator Antiretroviral Treatment and Care Department.

ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.

The Medicines Patent Pool advancing innovation, expanding access, promoting public health Charles Clift Chair, Medicines Patent Pool

Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.

Experience under the TAP: Determinants and experience with adherence in Burkina Faso Hospital and Community Sites in Burkina Faso Pascal NIAMBA, Cecile.

Dr. Yogan Pillay Deputy Director General National Department of Health, South Africa Monday 1 July 2013 OPERATIONAL AND PROGRAMMATIC CONSIDERATIONS IN.

Lagos, Nigeria: Is paying for HIV treatment bad for you? Comprehensive HIV-care in the General Hospital Lagos MSF-Holland/Germany.

Affordability of HIV/AIDS treatment in developing countries: modeling ARV drug price determinants for a better understanding of the market functioning.

How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.

Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.

Impacts of TRIPS on access to care The post-2005 issues Benjamin CORIAT University Paris 13 and ANRS ANRS – MoH Brazil Satellite Meeting Mexico, August.

2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.

Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.

Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.

Paula Munderi Department of Essential Drugs and Medicines Policy World Health Organization Access to essential medicines for HIV/AIDS - update on WHO activities.

WHO-Health Action International project on drug price comparisons A technical project of the WHO-Public interest NGO round table on access to medicines.

Review experiences of global ARV shortages Clarisse Morris, MA February 2006.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

Patient needs driven Research and Development Agenda in HIV Dr. Felipe Garcia de la Vega MSF Campaign for Access to Essential Medicines.

World Health Organization "3 by 5" Target Treat 3 million by 2005.

Access to Paediatric ARV Formulations Provisions for Children.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Treatment as Prevention and Treatment 2.0 Update UN Forum on AIDS, 24 June 2011 Nicole Seguy, Zhang Lan, WHO.

HIV/AIDS Track Session. Key Points Application of international reference price list during a national tender is a valuable tool for achieving optimal.

Ellen ‘t Hoen Médecins sans Frontières

Washington D.C., USA, July 2012www.aids2012.org Patent Oppositions in Argentina International AIDS Conference July 2012 M. Lorena Di Giano.

Sources and prices of newer ARVs: Prospects for Pricing and Availability XVI International AIDS Conference Satellite Session -- August 13, 2006 Médecins.

IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.

Aids treatment on the field Experiences from CAMEROON Swiss AIDS platform Aidsfocus Bern, April 2004 Béata UMUBYEYI.

Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,

The price trends of HIV/AIDS medicines: Finding and using data Dr. Perriëns Joseph Coordinator SSH Unit, WHO.

Scaling up Access to HIV treatment What can we learn for NCDs?

Making medicines, diagnostics and other commodities more affordable

Drug Pricing Policies and Challenges

World Health Organization

New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs) HIV positive.

Thokozani Kalua MBBS MSc Malawi Ministry of Health

Richard Laing, Kelly McGoldrick

Demand Forecasts for for HIV/AIDS ARV formulations

Presentation transcript:

2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006

Measuring prices of ARVS in pilot surveys -Very few ARV drugs available in surveys using WHO/HAI manual - some core list ARVs are rarely used now - sampling method inappropriate -In some countries ARVs are free or subsidized, - international reference prices not always not always available

Fluconazole price differences: example from pilot surveys Only data for some OIs available from pilot surveys

Mea -There is some information on prices for procurement purposes (UNICEF/WHO/UNAIDS/MSF Sources & Prices, MSF Untangling the Web) -Website data bases (WHO GPRM, Gfund ) -Some studies -Need more information about the end user prices -HAI/WHO hope to develop a separate method for measuring total treatment cost of AIDS (and other chronic diseases). What kind of information on prices of ARVS is available?

Prices and acces issues in 2nd line ARVS : Lessons from the past (older ARVs) Generic competition (most existing patents before 1995) : –lower prices, to US$132 –And FDCs (3-in-1 pill) to improve adherence Quality sources -- many WHO prequalified generics Affordability and availability allowing more rapid scale-up

Older ARVs: competition lowering prices ( Lowest offered prices US$ for yearly triple- d4T + 3TC + NVP) June 2006, $132 Cipla

Are these lowprices still a barrier in access to ARVs? Example: MSF Survey in Nigeria to measure how affordable are the current user fees for a Nigerian patient in need of ART Income : nearly 50 % of the interviewed MSF patients (n= 89) live on < 36US$ monthly Monthly ART cost before enrollment in the free MSF-program: 40 US$ for ARVs

Answers to sources of financing ART (n=89)

61% 14% 17% 1% FINANCE out of govt.stock SIDE EFFECTS SOCIAL HEALTH OK FAILURE TO IMPROVE OTHER 72% of all ARV experienced interviewed people (n= 122) had ART interruption : causes? 1% 6%

Source: DST/AIDS

11 Current Prices of 2 nd -Line ARVs Price of 2 nd -Line treatment as average of the 12 combinations recommended in the new draft WHO guidelines Source: CHAI (average annual cost in US$ reported by GPRM) $6, 000 $1,400 10x $140 40x 1 st Line (Africa) 2 nd Line (Africa) 2 nd Line ( Middle Income)

Abbott price for LPV/r ( yearly,US$, in 2005)

How to decrease recent ARVs prices? Enabling Factors for Starting & Scaling Up ARV Treatment were: Reductions in prices of 1 st line treatments through generic competition Simplification of treatment (esp. development and use of FDCs) WHO prequalification

Situation post unless IP flexibilities used

ADULT JUNIOR BABY Fixed-Dose Combination of d4T/3TC/NVP FDC for adult and children

No adapted formulations..... or some adapted R&D but not accesible « Now you can take KALETRA in.. 4 tablets, with or without food, and with no refrigeration requirements ». Keep at –2 to 8 Cº. <25ºC during two months

Post unless IP flexibilities used ADULT JUNIOR BABY Fixed-Dose Combination of d4T/3TC/NVP

New drugs for chronic diseases …. we will face same challenges in other chronic diseases as new medicines are developed for richer nations chronic patients. Will they be affordable and adapted for developing nations??

AIDS IS ONE CHRONIC DISEASE. ACCESS TO NEWER AND ADAPTED TREATMENTS WILL BE NECESSARY EVERYWHERE Since more patients in the future will need them, we need to start thinking about getting affordable and available second line drugs now.